Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received FDA approval for its clinical trial application for KC1086 tablets, a novel small molecule inhibitor targeting Lysine Acetyltransferase 6 (KAT6) for the treatment of advanced recurrent or metastatic solid tumors [2] Company Summary - The drug KC1086 is fully developed by Kangchen Pharmaceutical and features a new structure with high potency and selectivity [2] - The clinical trial for KC1086 is currently progressing in an orderly manner [2]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has successfully completed the enrollment of the first subject in the Phase I clinical study (KC1086-I-01) evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of KC1086 for the treatment of advanced recurrent or metastatic solid tumors [1] Group 1 - KC1086 is a small molecule inhibitor with a novel structure that selectively targets Lysine Acetyltransferase 6 (KAT6) [1] - The drug is entirely developed by Beijing Kangchen Pharmaceutical Co., Ltd. [1] - The clinical study aims to assess the drug's potential in treating advanced recurrent or metastatic solid tumors [1]